The preliminary public providing (IPO) of specialty chemical manufacturing firm Tatva Chintan Pharma Chem, opened for subscription earlier at this time and received oversubscribed inside a number of hours itself. So far, the problem was subscribed 4.50 occasions by the top of the primary day of bidding.
It acquired bids for 1,46,85,125 shares throughout each the inventory exchanges towards 32,61,882 shares on provide, information from the BSE confirmed.
At the top of the primary day, the shares allotted for the Qualified Institutional Buyers (QIBs) have been subscribed 0.50 occasions, whereas these for Non Institutional Investors received subscribed 1.13 occasions and that of Retail Individual Investors (RIIs) was subscribed 8.23 occasions, the info confirmed.
The Vadodara-based firm is into specialty chemical manufacturing and it exports most of its merchandise to over 25 nations, together with the US, China, Germany, Japan, South Africa and the UK.
The Tatva Chintan IPO shall be accessible for subscription until Tuesday, July 20, 2021, and the value band of the Vadodara-based agency has been mounted at Rs 1,073-1,083 per share. The public concern is predicted to fetch as much as Rs 500 crore.
Investors who want to subscribe to Tatva Chintan IPO can bid in a number of 13 fairness shares and multiples thereafter. At the higher worth band, they are going to be shelling out Rs 14,079 to get a single lot of Tatva Chintan Pharma Chem. The shares shall be listed on each BSE in addition to the National Stock Exchange (NSE).
The candidates must also observe that the cut-off time for UPI mandate affirmation is Thursday, July 22, 2021, upto 12:00 pm. If they fail to take action then their software is probably not thought-about.
Tatva Chintan IPO contains Rs 225 crore via a contemporary concern of shares and the remaining Rs 275 crore shall be a suggestion on the market (OFS) by the prevailing buyers.
ICICI Securities and JM Financial are the guide operating lead managers to the Tatva Chintan Pharma Chem IPO whereas Link Intime India is the registrar of the problem.
The analysis groups at Motilal Oswal Financial Services and Anand Rathi Share and Stock Brokers of their respective notes have advisable “Subscribe” to the provide.
Motilal Oswal Financial Services in its IPO observe said that, “We like TCPCL due its leadership position, wide product portfolio, strong client relationship and high entry barriers. The company is expected to witness strong growth for next 2-3 years given its expansion plans. It is well placed to tap opportunity in the fast growing specialty chemical space with increasing focus on green chemistry by leveraging its strong R&D capabilities. The issue is valued at 45.9x FY21 P/E on post issue basis, which appears reasonable compared to peers (avg. P/E of 59x), as it enjoys higher earnings growth (62 per cent CAGR vs. avg. 38 per cent CAGR for peers over FY18-21). Hence, we recommend Subscribe.”